Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 4Thyroid Cancer, Papillary 1Neoplasm Metastasis 1Differentiated Thyroid Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 46Specimen Handling 45Biopsy 38Magnetic Resonance Spectroscopy 36Paclitaxel 22Nivolumab 22Carboplatin 21Gemcitabine 20Radiosurgery 18Irinotecan 17Ipilimumab 13Cisplatin 13Capecitabine 12130-nm albumin-bound paclitaxel 12trastuzumab deruxtecan 11Taxes 11Pemetrexed 11Leucovorin 11Fluorouracil 11Cetuximab 11olaparib 10Cyclophosphamide 10Bevacizumab 10durvalumab 9abemaciclib 9Oxaliplatin 9palbociclib 8X-Rays 8Fulvestrant 8Drug Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Iodine-124 × 90 days × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡